ClinicalTrials.gg
CompletedNCT02500212Updated Jul 31, 2020

Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients

A Phase 4 interventional study of ENVARSUS® and ADVAGRAF® in Organ or Tissue Transplant; Complications, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 7 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-31.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Open-label, multicentre, randomized clinical trial to compare the pharmacokinetics of ENVARSUS® tablets and ADVAGRAF® capsules administered once daily in adult de-novo kidney transplant patients.

02

Conditions studied

  • Organ or Tissue Transplant; Complications
03

In context

Lead sponsor

Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recipients of a kidney transplant from a deceased donor or a living donor

Exclusion criteria

Exclusion Criteria:

  • Recipient of any transplanted organ other than a kidney;
  • Recipients of a bone marrow or stem cell transplant;
  • Recipients of a kidney from a cardiac death donor;
  • Recipients of a kidney from an ABO incompatible donor;
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    ENVARSUS tablets

    Envarsus® (tacrolimus) prolonged-release tablets provided in 0.75 mg, 1.0 mg and 4.0 mg dose strengths. Envarsus® tablets will be administered orally once daily in the morning

    Drug: ENVARSUS®

  • Active comparator
    ADVAGRAF capsules

    Advagraf® (tacrolimus) prolonged-release hard capsules provided in 0.5 mg, 1.0 mg, 3.0 mg and 5.0 mg dose strengths. Advagraf® capsules will be administered orally once daily in the morning

    Drug: ADVAGRAF®

Interventions

06

What researchers measure

Primary outcomes

  1. Tacrolimus Area under the curve (AUC 0-24h)r h*pg/mL

    Time frame: pre-dose, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12.0, 16.0, 20.0, 24.0 hr post-dose

Secondary outcomes

  1. Tacrolimus concentration 24 hours post-dose (C24hr) pg/mL

    Whole blood trough drug concentration 24hour post dose

    Time frame: 24.0 hr post-dose

  2. Serum creatinine (mg/dL)

    Time frame: before dosing

  3. estimated glomerular filtration rate (eGFR) mL/min;

    Time frame: before dosing

  4. Heart Rate, (beats per minute)

    Time frame: before dosing

  5. Qt (milliseconds)

    Time frame: before dosing

07

Study locations

7 sites
  • Nephrology Department Hopital La Cavale Blanche
    Brest, 296009, France
  • Clinique de Nephrologie CHU Grenoble
    Grenoble, 38043, France
  • CHU Limoges
    Limoges, 87042, France
  • Service de Nephrologie
    Montpellier, 34295, France
  • Unité de transplantation rénale -Hopital Pasteur
    Nice, France
  • Nephrology department CHU de Saint-Etienne Hospital Nord
    Saint Etienne, 42055, France
  • CHU Rangueil, 1 avenue J Poulhes TSA 50032.
    Toulouse, 31400, France
08

References and documents

Publications

  • Kamar N, Cassuto E, Piotti G, Govoni M, Ciurlia G, Geraci S, Poli G, Nicolini G, Mariat C, Essig M, Malvezzi P, Le Meur Y, Garrigue V, Del Bello A, Rostaing L. Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study. Adv Ther. 2019 Feb;36(2):462-477. doi: 10.1007/s12325-018-0855-1. Epub 2018 Dec 14. PubMed 30552587 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2015
First posted
Jul 16, 2015
Start
Jul 2015
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Last update
Jul 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02500212
Responsible party
Sponsor
First posted
Jul 16, 2015
Start date
Jul 2015
Primary completion
Jun 2016
Completion
Jun 2016
Last update
Jul 31, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion